

Yann Joly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594705/publications.pdf>

Version: 2024-02-01

65
papers

1,515
citations

430874

18
h-index

345221

36
g-index

67
all docs

67
docs citations

67
times ranked

2524
citing authors

#	ARTICLE	IF	CITATIONS
1	Prepublication data sharing. <i>Nature</i> , 2009, 461, 168-170.	27.8	243
2	Data Sharing in the Post-Genomic World: The Experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). <i>PLoS Computational Biology</i> , 2012, 8, e1002549.	3.2	100
3	Genetic discrimination and life insurance: a systematic review of the evidence. <i>BMC Medicine</i> , 2013, 11, 25.	5.5	98
4	GA4GH: International policies and standards for data sharing across genomic research and healthcare. <i>Cell Genomics</i> , 2021, 1, 100029.	6.5	94
5	Epigenetics, ethics, law and society: A multidisciplinary review of descriptive, instrumental, dialectical and reflexive analyses. <i>Social Studies of Science</i> , 2019, 49, 785-810.	2.5	81
6	Comparative Approaches to Genetic Discrimination: Chasing Shadows?. <i>Trends in Genetics</i> , 2017, 33, 299-302.	6.7	63
7	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&#amp;l). <i>Journal of Personalized Medicine</i> , 2021, 11, 511.	2.5	59
8	Ethical issues of CRISPR technology and gene editing through the lens of solidarity. <i>British Medical Bulletin</i> , 2017, 122, 17-29.	6.9	57
9	Genetic discrimination in private insurance: global perspectives. <i>New Genetics and Society</i> , 2010, 29, 351-368.	1.2	51
10	Controlled Access under Review: Improving the Governance of Genomic Data Access. <i>PLoS Biology</i> , 2015, 13, e1002339.	5.6	42
11	Life insurance: genomic stratification and risk classification. <i>European Journal of Human Genetics</i> , 2014, 22, 575-579.	2.8	41
12	Harm, hype and evidence: ELSI research and policy guidance. <i>Genome Medicine</i> , 2013, 5, 21.	8.2	39
13	Looking Beyond GINA: Policy Approaches to Address Genetic Discrimination. <i>Annual Review of Genomics and Human Genetics</i> , 2020, 21, 491-507.	6.2	38
14	Epigenome data release: a participant-centered approach to privacy protection. <i>Genome Biology</i> , 2015, 16, 142.	8.8	34
15	Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination. <i>Frontiers in Genetics</i> , 2018, 9, 202.	2.3	29
16	Points-to-consider on the return of results in epigenetic research. <i>Genome Medicine</i> , 2019, 11, 31.	8.2	27
17	Genomic databases access agreements: legal validity and possible sanctions. <i>Human Genetics</i> , 2011, 130, 441-449.	3.8	24
18	International federation of genomic medicine databases using GA4GH standards. <i>Cell Genomics</i> , 2021, 1, 100032.	6.5	22

#	ARTICLE	IF	CITATIONS
19	Physicians, genetics and life insurance. <i>Cmaj</i> , 2004, 170, 1421-1423.	2.0	19
20	Benefits and barriers in the design of harmonized access agreements for international data sharing. <i>Scientific Data</i> , 2019, 6, 297.	5.3	18
21	Establishing the International Genetic Discrimination Observatory. <i>Nature Genetics</i> , 2020, 52, 466-468.	21.4	18
22	Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors. <i>Journal of Genetic Counseling</i> , 2015, 24, 1022-1036.	1.6	17
23	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. <i>Frontiers in Genetics</i> , 2017, 8, 128.	2.3	17
24	Genetic discrimination: introducing the Asian perspective to the debate. <i>Npj Genomic Medicine</i> , 2021, 6, 54.	3.8	16
25	Risk of re-identification of epigenetic methylation data: a more nuanced response is needed. <i>Clinical Epigenetics</i> , 2015, 7, 45.	4.1	14
26	Disease Resistance and the Definition of Genetic Enhancement. <i>Frontiers in Genetics</i> , 2017, 8, 40.	2.3	13
27	South Korea: in the midst of a privacy reform centered on data sharing. <i>Human Genetics</i> , 2018, 137, 627-635.	3.8	13
28	Introduction: the why and whither of genomic data sharing. <i>Human Genetics</i> , 2018, 137, 569-574.	3.8	13
29	Genomics for All: International Open Science Genomics Projects and Capacity Building in the Developing World. <i>Frontiers in Genetics</i> , 2019, 10, 95.	2.3	13
30	Evolving data access policy: The Canadian context. <i>Facets</i> , 2017, 1, 138-147.	2.4	13
31	Falling giants and the rise of gene editing: ethics, private interests and the public good. <i>Human Genomics</i> , 2017, 11, 20.	2.9	12
32	Issues related to family history of cancer at the end of life: a palliative care providers' survey. <i>Familial Cancer</i> , 2018, 17, 303-307.	1.9	12
33	Open science and community norms. <i>Medical Law International</i> , 2012, 12, 92-120.	1.1	10
34	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. <i>Cell Genomics</i> , 2021, 1, 100033.	6.5	10
35	Harnessing Omics Sciences, Population Databases, and Open Innovation Models for Theranostics-Guided Drug Discovery and Development. <i>Drug Development Research</i> , 2012, 73, 439-446.	2.9	9
36	Social, ethical and legal considerations raised by the discovery and patenting of the BRCA1 and BRCA2 genes. <i>New Genetics and Society</i> , 2014, 33, 167-180.	1.2	9

#	ARTICLE	IF	CITATIONS
37	DNA Testing for Family Reunification in Canada: Points to Consider. <i>Journal of International Migration and Integration</i> , 2017, 18, 391-404.	1.4	9
38	Modeling consent in the time of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, Isaa020.	1.6	9
39	Selling direct-to-consumer epigenetic tests: are we ready?. <i>Nature Reviews Genetics</i> , 2020, 21, 335-336.	16.3	9
40	Human rights in the postgenomic era: Challenges and opportunities arising with epigenetics. <i>Social Science Information</i> , 2020, 59, 12-34.	1.6	8
41	Is it research or is it clinical? Revisiting an old frontier through the lens of next-generation sequencing technologies. <i>European Journal of Medical Genetics</i> , 2018, 61, 634-641.	1.3	7
42	The omics of our lives: practices and policies of direct-to-consumer epigenetic and microbiomic testing companies. <i>New Genetics and Society</i> , 2021, 40, 541-569.	1.2	7
43	A step forward, but still inadequate: Australian health professionals' views on the genetics and life insurance moratorium. <i>Journal of Medical Genetics</i> , 2022, 59, 817-826.	3.2	6
44	Engaged genomic science produces better and fairer outcomes: an engagement framework for engaging and involving participants, patients and publics in genomics research and healthcare implementation. <i>Wellcome Open Research</i> , 2021, 6, 311.	1.8	6
45	Addressing cancer family history at the end of life: How frequent, relevant, and feasible is it? A survey of palliative care providers. <i>Palliative Medicine</i> , 2019, 33, 856-858.	3.1	5
46	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 726.	2.5	5
47	Regulatory approval for new pharmacogenomic tests: a comparative overview. <i>Food and Drug Law Journal</i> , 2011, 66, 1-24, i.	0.4	5
48	Addressing Privacy Concerns in Sharing Viral Sequences and Minimum Contextual Data in a Public Repository During the COVID-19 Pandemic. <i>Frontiers in Genetics</i> , 2021, 12, 716541.	2.3	5
49	Disclosure of insurability risks in research and clinical consent forms. <i>Global Bioethics</i> , 2016, 27, 38-49.	1.5	4
50	Communication of genetic information in the palliative care context: Ethical and legal issues. <i>Medical Law International</i> , 2018, 18, 219-240.	1.1	4
51	Country Reports. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 582-704.	0.9	4
52	What do cancer patients' relatives think about addressing cancer family history and performing genetic testing in palliative care?. <i>European Journal of Human Genetics</i> , 2020, 28, 213-221.	2.8	4
53	Communicating science: epigenetics in the spotlight. <i>Environmental Epigenetics</i> , 2020, 6, dvaa015.	1.8	4
54	The commercialization of genomic research in Canada. <i>Healthcare Policy</i> , 2010, 6, 24-32.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 597-605.	2.0	3
56	Currents in Contemporary Bioethics: Open Access as Benefit Sharing? The Example of Publicly Funded Large-Scale Genomic Databases. <i>Journal of Law, Medicine and Ethics</i> , 2012, 40, 143-146.	0.9	3
57	Assessing public opinions on the likelihood and permissibility of gene editing through construal level theory. <i>New Genetics and Society</i> , 2021, 40, 473-497.	1.2	3
58	Anti-Selection & Genetic Testing in Insurance: An Interdisciplinary Perspective. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 139-154.	0.9	3
59	Clinical exome sequencing in France and Quebec: what are the challenges? What does the future hold?. <i>Life Sciences, Society and Policy</i> , 2018, 14, 17.	3.2	2
60	Overcoming Biases Together: Normative Stakes of Interdisciplinarity in Bioethics. <i>AJOB Empirical Bioethics</i> , 2020, 11, 20-23.	1.6	2
61	Survey of palliative care providers'™ needs, perceived roles, and ethical concerns about addressing cancer family history at the end of life. <i>Palliative and Supportive Care</i> , 2021, 19, 217-222.	1.0	2
62	Genetic discrimination views in online discussion forums: Perspectives from Canadian forumites. <i>Journal of Genetic Counseling</i> , 2021, 30, 1613-1628.	1.6	2
63	A decision tool to guide the ethics review of a challenging breed of emerging genomic projects. <i>European Journal of Human Genetics</i> , 2016, 24, 1099-1103.	2.8	0
64	Anti-selection & Genetic Testing in Insurance: An Interdisciplinary Perspective. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
65	Genetic Discrimination in Access to Life Insurance: Does Ukrainian Legislation Offer Sufficient Protection against the Adverse Consequences of the Genetic Revolution to Insurance Applicants?. <i>Laws</i> , 2022, 11, 2.	1.1	0